酵素替代療法市場－全球產業規模、佔有率、趨勢、機會及預測（按產品、疾病、給藥途徑、最終用戶、地區和競爭格局分類，2021-2031年）

全球酵素替代療法市場預計將從 2025 年的 107.3 億美元成長到 2031 年的 168.5 億美元，複合年成長率為 7.81%。

酵素替代療法是治療罕見遺傳疾病（主要是溶小體儲積症症）患者的重要治療選擇，用於補充缺失或不足的酵素。市場成長的促進因素包括：已確診遺傳疾病盛行率的上升、重組DNA技術的進步使得人類酵素的大規模生產成為可能，以及孤兒藥認定等政府支持性法規。這些促進因素共同推動市場擴張，維持強大的開發平臺，並滿足了以往服務不足的患者群體的需求。

然而，由於研發和治療治療方法高成本，該領域面臨許多挑戰，這往往導致報銷困難和病患用藥受限。儘管存在這些經濟障礙，該行業仍然致力於創新。根據美國藥品研究與製造商協會（PhRMA）統計，到2024年，將有超過560種針對罕見疾病的新藥正在研發中，其中包括酵素缺乏症的治療方法，這表明該行業在解決這些複雜的疾病方面持續投入。

市場促進因素

監管核准流程和孤兒藥認定是重要的市場成長催化劑，能夠降低罕見疾病治療藥物研發相關的財務風險。監管機構提供市場獨佔權、臨床試驗稅額扣抵和快速核准等重要獎勵，促使製藥公司儘管患者群體較小，仍致力於開發酶缺乏症的治療藥物。這種支持在近期監管機構對服務不足疾病治療方法的優先核准中得到了充分體現。例如，美國食品藥物管理局（FDA）藥物評估與研究中心在其2024年1月發布的《2023年新藥核准情況報告》中指出，2023年核准的55種新藥中有28種被認定為孤兒藥，凸顯了這些核准途徑在新型罕見病治療藥物商業化過程中發揮的重要過程。

同時，強大的臨床試驗管線和策略性研發投資正在提升酵素替代療法的可近性和療效。製藥公司正集中資源開發新一代製劑，以提高組織標靶性和穩定性，並透過內部成長和收購積極拓展市場佔有率。這一發展勢頭帶來了可觀的財務回報，並擴大了全球患者的用藥範圍。根據Change Group於2024年4月發布的2023年度報告，該公司罕見疾病部門的銷售額達到5.4億歐元，以外匯匯率計算成長了65%，這主要得益於其不斷擴大的產品組合。同樣，BioMarin Pharmaceuticals於2024年2月宣布，其2023年全年總收入將達到24.2億美元，比上年成長15%，進一步印證了該業務板塊的強勁財務實力。

市場挑戰

酵素替代療法（ERT）的研發和應用成本高昂，構成了嚴重的報銷障礙，並直接阻礙了市場擴張。這些複雜的生物製劑生產難度高，且目標患者群較小，導致每位患者的治療費用居高不下，對醫療預算造成巨大壓力。因此，無論是私人還是公共支付方，都經常採取嚴格的成本控制措施，包括漫長的價格談判和嚴格的報銷標準。這些財務障礙阻礙了已通過核准治療方法的順利商業化，造成了瓶頸，使得現有療法無法有效地惠及目標患者群體。

監管核准和報銷系統之間的摩擦導致患者獲得治療的時間顯著延遲，實際上縮短了製藥公司實現產生收入的時間。資金籌措的延遲阻礙了持續投資，並限制了市場服務已確診患者群體的能力。這種延遲用藥的趨勢在主要地區均有體現：根據歐洲製藥工業協會聯合會（EFPIA）的數據，截至2024年，歐洲市場患者在獲得監管核准後獲得創新藥物的平均等待時間已達578天。這些漫長的報銷延遲凸顯了藥物可及性挑戰的嚴峻性，並持續限制全球市場的規模化發展。

市場趨勢

新一代長效酵素療法的進步正在重塑市場格局。這些經過基因工程改造的蛋白質具有較低的免疫抗原性和更長的半衰期，可取代傳統的重組酵素。這種轉變減輕了傳統療法頻繁給藥的沉重負擔，從而改善了臨床療效並提高了患者的長期依從性。隨著醫療機構越來越重視療效更佳、使用更便利的治療方法，這些先進生物製藥的應用速度正在加速。根據賽諾菲於2025年4月發布的《2025年第一第一季財務業績報告》，其新一代療法Nexiazyme第一季的銷售額達到1.95億歐元，年成長26.3%，這主要得益於活性化的患者從傳統標準治療方法轉向使用此類療法。

同時，Chaperone介導的聯合治療正被引入作為一種重要策略，以解決外源性酵素在血液循環中的不穩定性問題。合併使用藥理Chaperone可以穩定治療性酶，使更高濃度的活性蛋白能夠到達標靶溶小體。這對於難治性疾病表現型尤其有效。這種雙機制方法透過滿足罕見疾病領域尚未滿足的需求（在這些領域，單藥療法缺乏持久性），已被證明具有商業性可行性。根據Amicus Therapeutics公司於2025年2月發布的“2024會計年度全年財務報告”，新型聯合治療“Pombility”和“Opfolder”在2024會計年度的銷售額總合達到7020萬美元，證實了市場對這種協同治療方法的強勁需求。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球酵素替代療法市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 依產品（加爾硫酸酶、維拉葡糖苷酶α、拉羅尼酶、阿斯福他酶α、其他）
  • 疾病類型（外分泌胰臟功能不全（EPI）、龐貝氏症、謝伊症候群、馬羅托-拉米氏症候群、高雪氏症、其他）
  • 依給藥途徑（口服、腸外、其他）
  • 依最終使用者（醫院/診所、門診手術中心、其他）分類
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章 北美酵素替代療法市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

7. 歐洲酵素替代療法市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

8. 亞太地區酵素替代療法市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

9. 中東和非洲酵素替代療法市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章 南美洲酵素替代療法市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進要素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 最新進展

第13章 全球酵素替代療法市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的可能性
• 供應商電力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Takeda pharmaceutical Company Ltd.
• Leadiant Biosciences Inc.
• Biomarin Pharmaceuticals Inc.
• Genzyme Corporation
• Pfizer Inc.
• Shire plc
• Sigma-Tau Pharmaceuticals, Inc
• Essential Pharmaceuticals Limited
• Merck KGa
• AbbVie Inc

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Enzyme Replacement Therapy Market is projected to expand from USD 10.73 Billion in 2025 to USD 16.85 Billion by 2031, registering a compound annual growth rate of 7.81%. Enzyme Replacement Therapy serves as a critical therapeutic intervention by substituting absent or deficient enzymes, primarily for patients suffering from rare genetic conditions such as lysosomal storage diseases. The market's growth is fundamentally anchored by the increasing prevalence of diagnosed genetic disorders, breakthroughs in recombinant DNA technology that facilitate scalable human enzyme production, and supportive government regulations like orphan drug designations. These drivers collectively sustain a robust development pipeline, fostering market expansion by addressing previously unmet medical needs within underserved patient populations.

However, the sector faces a substantial obstacle in the form of high costs related to the development and administration of these therapies, which frequently result in reimbursement difficulties and limited patient access. Despite these financial hurdles, the industry remains deeply committed to innovation. According to the Pharmaceutical Research and Manufacturers of America, in 2024, there were over 560 novel medicines in development for rare diseases, including treatments for enzyme deficiency disorders, demonstrating a sustained investment in resolving these complex medical conditions.

Market Driver

Regulatory approval pathways and favorable orphan drug designations act as significant catalysts for market growth by reducing the financial risks involved in developing treatments for rare conditions. Regulatory bodies offer essential incentives, including market exclusivity, tax credits for clinical trials, and accelerated review processes, which motivate pharmaceutical companies to target enzyme deficiency disorders despite the small size of patient populations. This support is clearly reflected in recent approval trends, where agencies prioritize therapies for underserved conditions. For instance, the FDA Center for Drug Evaluation and Research noted in its 'New Drug Therapy Approvals 2023' report from January 2024 that 28 of the 55 novel drugs approved in 2023 were designated as orphan drugs, highlighting the crucial role these pathways play in commercializing new rare disease therapies.

Simultaneously, robust clinical trial pipelines and strategic R&D investments are enhancing the availability and efficacy of enzyme replacement therapies. Pharmaceutical developers are increasingly directing resources toward next-generation formulations that provide better tissue targeting and stability, while also aggressively expanding their market footprint through organic growth and acquisitions. This momentum is generating significant financial returns and broadening global patient access. As reported by Chiesi Group in their '2023 Annual Report' in April 2024, the company's Rare Diseases Business Unit achieved sales of €540 million, representing a 65% growth at constant exchange rates due to portfolio expansion. Similarly, BioMarin Pharmaceutical Inc. announced in February 2024 that total revenues for the full year 2023 reached $2.42 billion, a 15% increase compared to the prior year, underscoring the sector's financial health.

Market Challenge

The substantial costs associated with developing and administering Enzyme Replacement Therapy (ERT) create major reimbursement hurdles that directly impede market expansion. Because these complex biological treatments are difficult to manufacture and target small patient populations, they often command high per-patient prices that place a significant strain on healthcare budgets. Consequently, both private and public payers frequently implement strict cost-containment measures, such as prolonged price negotiations and restrictive coverage criteria. These financial barriers obstruct the seamless commercialization of approved therapies, creating a bottleneck where available treatments fail to reach the intended patient base efficiently.

This friction between regulatory approval and reimbursement results in considerable delays in patient access, effectively shortening the revenue-generating window for pharmaceutical companies. The lag in securing funding discourages sustained investment and limits the market's capacity to serve the diagnosed population. This trend of delayed availability is quantifiable in key regions; according to the European Federation of Pharmaceutical Industries and Associations, in 2024, the average waiting time for patients to access innovative new medicines following regulatory approval reached 578 days across European markets. Such extended reimbursement delays highlight the severity of the access challenge, which continues to suppress the scalable expansion of the global market.

Market Trends

The market is being reshaped by the advancement of next-generation long-acting enzyme variants, which are replacing standard recombinant enzymes with engineered proteins that offer reduced immunogenicity and extended half-lives. This shift addresses the significant burden of frequent infusions associated with legacy therapies, thereby improving clinical outcomes and long-term patient adherence. As healthcare providers increasingly prioritize treatments that offer superior efficacy and convenience, the adoption rates for these advanced biologics have accelerated. According to Sanofi's 'Q1 2025 Results' report from April 2025, sales for the next-generation therapy Nexviazyme reached €195 million in the first quarter, marking a 26.3% increase driven by the active transition of patients from older standard-of-care regimens.

Simultaneously, the integration of chaperone-mediated combination therapies is gaining traction as a critical strategy to address the instability of exogenous enzymes in the bloodstream. By co-administering pharmacological chaperones, manufacturers can stabilize the therapeutic enzyme, ensuring that higher levels of active protein reach the target lysosomes, which is particularly effective for difficult-to-treat disease phenotypes. This dual-mechanism approach is proving its commercial viability by meeting unmet needs in the rare disease space where monotherapies have historically lacked durability. According to Amicus Therapeutics in their 'Full-Year 2024 Financial Results' report from February 2025, net product sales for the novel combination therapy Pombiliti and Opfolda totaled $70.2 million for the full year 2024, underscoring the strong market uptake of this synergistic treatment modality.

Key Market Players

• Takeda pharmaceutical Company Ltd.
• Leadiant Biosciences Inc.
• Biomarin Pharmaceuticals Inc.
• Genzyme Corporation
• Pfizer Inc.
• Shire plc
• Sigma-Tau Pharmaceuticals, Inc
• Essential Pharmaceuticals Limited
• Merck KGa
• AbbVie Inc

Report Scope

In this report, the Global Enzyme Replacement Therapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Enzyme Replacement Therapy Market, By Products

• Galsulfase
• Velaglucerase Alfa
• Laronidase
• Asfotasealfa
• Others

Enzyme Replacement Therapy Market, By Diseases

• Exocrine Pancreatic Insufficiency (EPI)
• Pompe Disease
• Scheie Syndrome
• Maroteaux-Lamy Syndrome
• Gaucher Disease
• Others

Enzyme Replacement Therapy Market, By Route of Administrations

• Oral
• Parenteral
• Others

Enzyme Replacement Therapy Market, By End User

• Hospitals & Clinics
• Ambulatory Surgical Centers
• Others

Enzyme Replacement Therapy Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Enzyme Replacement Therapy Market.

Available Customizations:

Global Enzyme Replacement Therapy Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Enzyme Replacement Therapy Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Products (Galsulfase, Velaglucerase Alfa, Laronidase, Asfotasealfa, Others)
  • 5.2.2. By Diseases (Exocrine Pancreatic Insufficiency (EPI), Pompe Disease, Scheie Syndrome, Maroteaux-Lamy Syndrome, Gaucher Disease, Others)
  • 5.2.3. By Route of Administrations (Oral, Parenteral, Others)
  • 5.2.4. By End User (Hospitals & Clinics, Ambulatory Surgical Centers, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Enzyme Replacement Therapy Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Products
  • 6.2.2. By Diseases
  • 6.2.3. By Route of Administrations
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Enzyme Replacement Therapy Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Products
      • 6.3.1.2.2. By Diseases
      • 6.3.1.2.3. By Route of Administrations
      • 6.3.1.2.4. By End User
  • 6.3.2. Canada Enzyme Replacement Therapy Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Products
      • 6.3.2.2.2. By Diseases
      • 6.3.2.2.3. By Route of Administrations
      • 6.3.2.2.4. By End User
  • 6.3.3. Mexico Enzyme Replacement Therapy Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Products
      • 6.3.3.2.2. By Diseases
      • 6.3.3.2.3. By Route of Administrations
      • 6.3.3.2.4. By End User

7. Europe Enzyme Replacement Therapy Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Products
  • 7.2.2. By Diseases
  • 7.2.3. By Route of Administrations
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Enzyme Replacement Therapy Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Products
      • 7.3.1.2.2. By Diseases
      • 7.3.1.2.3. By Route of Administrations
      • 7.3.1.2.4. By End User
  • 7.3.2. France Enzyme Replacement Therapy Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Products
      • 7.3.2.2.2. By Diseases
      • 7.3.2.2.3. By Route of Administrations
      • 7.3.2.2.4. By End User
  • 7.3.3. United Kingdom Enzyme Replacement Therapy Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Products
      • 7.3.3.2.2. By Diseases
      • 7.3.3.2.3. By Route of Administrations
      • 7.3.3.2.4. By End User
  • 7.3.4. Italy Enzyme Replacement Therapy Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Products
      • 7.3.4.2.2. By Diseases
      • 7.3.4.2.3. By Route of Administrations
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Enzyme Replacement Therapy Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Products
      • 7.3.5.2.2. By Diseases
      • 7.3.5.2.3. By Route of Administrations
      • 7.3.5.2.4. By End User

8. Asia Pacific Enzyme Replacement Therapy Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Products
  • 8.2.2. By Diseases
  • 8.2.3. By Route of Administrations
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Enzyme Replacement Therapy Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Products
      • 8.3.1.2.2. By Diseases
      • 8.3.1.2.3. By Route of Administrations
      • 8.3.1.2.4. By End User
  • 8.3.2. India Enzyme Replacement Therapy Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Products
      • 8.3.2.2.2. By Diseases
      • 8.3.2.2.3. By Route of Administrations
      • 8.3.2.2.4. By End User
  • 8.3.3. Japan Enzyme Replacement Therapy Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Products
      • 8.3.3.2.2. By Diseases
      • 8.3.3.2.3. By Route of Administrations
      • 8.3.3.2.4. By End User
  • 8.3.4. South Korea Enzyme Replacement Therapy Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Products
      • 8.3.4.2.2. By Diseases
      • 8.3.4.2.3. By Route of Administrations
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Enzyme Replacement Therapy Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Products
      • 8.3.5.2.2. By Diseases
      • 8.3.5.2.3. By Route of Administrations
      • 8.3.5.2.4. By End User

9. Middle East & Africa Enzyme Replacement Therapy Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Products
  • 9.2.2. By Diseases
  • 9.2.3. By Route of Administrations
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Enzyme Replacement Therapy Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Products
      • 9.3.1.2.2. By Diseases
      • 9.3.1.2.3. By Route of Administrations
      • 9.3.1.2.4. By End User
  • 9.3.2. UAE Enzyme Replacement Therapy Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Products
      • 9.3.2.2.2. By Diseases
      • 9.3.2.2.3. By Route of Administrations
      • 9.3.2.2.4. By End User
  • 9.3.3. South Africa Enzyme Replacement Therapy Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Products
      • 9.3.3.2.2. By Diseases
      • 9.3.3.2.3. By Route of Administrations
      • 9.3.3.2.4. By End User

10. South America Enzyme Replacement Therapy Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Products
  • 10.2.2. By Diseases
  • 10.2.3. By Route of Administrations
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Enzyme Replacement Therapy Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Products
      • 10.3.1.2.2. By Diseases
      • 10.3.1.2.3. By Route of Administrations
      • 10.3.1.2.4. By End User
  • 10.3.2. Colombia Enzyme Replacement Therapy Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Products
      • 10.3.2.2.2. By Diseases
      • 10.3.2.2.3. By Route of Administrations
      • 10.3.2.2.4. By End User
  • 10.3.3. Argentina Enzyme Replacement Therapy Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Products
      • 10.3.3.2.2. By Diseases
      • 10.3.3.2.3. By Route of Administrations
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Enzyme Replacement Therapy Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Takeda pharmaceutical Company Ltd.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Leadiant Biosciences Inc.
• 15.3. Biomarin Pharmaceuticals Inc.
• 15.4. Genzyme Corporation
• 15.5. Pfizer Inc.
• 15.6. Shire plc
• 15.7. Sigma-Tau Pharmaceuticals, Inc
• 15.8. Essential Pharmaceuticals Limited
• 15.9. Merck KGa
• 15.10. AbbVie Inc

16. Strategic Recommendations

17. About Us & Disclaimer